Alkermes plc (ALKS)
| Market Cap | 7.72B +53.8% |
| Revenue (ttm) | 1.75B +15.3% |
| Net Income | -351,000 |
| EPS | -0.01 |
| Shares Out | 168.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,673,316 |
| Open | 44.19 |
| Previous Close | 44.54 |
| Day's Range | 44.07 - 45.94 |
| 52-Week Range | 27.00 - 55.67 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 56.21 (+22.38%) |
| Earnings Date | Nov 3, 2026 |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu... [Read more]
Financial Performance
In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $56.21, which is an increase of 22.38% from the latest price.
News
Alkermes announces plans to present data across portfolios at NEI congress
Alkermes (ALKS) announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute, NEI, Fall Congress, taking place Nov. 5-8, 2026 in Col...
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall C...
Alkermes price target raised to $68 from $65 at Wells Fargo
Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Alkermes (ALKS) to $68 from $65 and keeps an Overweight rating on the shares. The firm likes the potential…
Alkermes price target raised to $50 from $43 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Alkermes (ALKS) to $50 from $43 and keeps a Neutral rating on the shares. The company reported a solid…
Alkermes to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat o...
Alkermes commercial performance solid in Q3, says H.C. Wainwright
H.C. Wainwright says Alkermes (ALKS) posted a solid commercial performance in Q3. The quarter saw some commercial performance beat expectations, offset by some misses, the analyst tells investors in a...
Alkermes Earnings Call Transcript: Q3 2026
Q3 proprietary-product sales rose 31% YoY to $417.3M, and 2026 guidance was reiterated. Pipeline momentum centers on orexin programs, with multiple clinical readouts expected over the coming year.
Alkermes Earnings release: Q3 2026
Alkermes released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Alkermes Slides: Q3 2026
Alkermes has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Alkermes Quarterly report: Q3 2026
Alkermes has published its Q3 2026 quarterly earnings report on November 3, 2026.
Alkermes reports Q3 EPS 9c, consensus (6c)
Reports Q3 revenue $480.1M, consensus $463.48M. “We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in...
Alkermes plc Reports Third Quarter 2026 Financial Results
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and prese...
Alkermes initiates Phase 2 study evaluating safety, efficacy of ALKS 7290
Alkermes (ALKS) announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive…
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in ad...
Alkermes to Report Third Quarter Financial Results on November 3, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third qu...
Alkermes reinstated with a Buy at Truist
Truist reinstated coverage of Alkermes (ALKS) with a Buy rating and $55 price target The company has effectively leveraged its base business to invest in a compelling orexin-2 receptor agonist…
Alkermes to present new data on alixorexton, LUMRYZ
Alkermes (ALKS) announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s, ESRS, 28th Co...
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the Europ...
Alkermes resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of Alkermes (ALKS) with a Neutral rating and $50 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite…
Alkermes price target raised to $61 from $58 at Baird
Baird raised the firm’s price target on Alkermes (ALKS) to $61 from $58 and keeps an Outperform rating on the shares following “impressive” OX2R proof-of-concept data in ADHD. Published first…
Alkermes data show measurable improvements in ADHD, says H.C. Wainwright
H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) after the company reported the first clinical evidence of an orexin-2 receptor agonist producing measurable improvements in attention-deficit/...
Alkermes jumps 8% to $46.99 after Phase I adult ADHD data
07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data
Alkermes announces Phase 1b results of ALKS 7290 in ADHD
Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor agonist in development for the treatment of...
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company's novel, investigational orexin 2 ...
Alkermes announces appointment of Whitaker to Board of Directors
Alkermes (ALKS) announced the appointment of a new independent director, Anne Whitaker, to the company’s Board of Directors. Whitaker most recently served as chief executive officer of Aerami Therapeu...